NEXIUM 20mg Retail Launch in the U.S. Targeted for 2014, Subject to Regulatory Approval Pfizer Updates Certain Elements of 2012 Financial Guidance to Reflect the Transaction NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription […]
PARSIPPANY, N.J., July 25, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of several new and extended contracts, including two new wins from Top 10 global pharmaceutical companies. Together the contracts are expected to generate total revenues of $29 million over the lives of the contracts. $12 – $13 million of revenue […]
Review Committee Recommends Sample Size of 10,900 Patients Based on Interim Analysis PARSIPPANY, NJ, Jul 02, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced it expects to complete patient enrollment of the pivotal Phase 3 CHAMPION PHOENIX trial of cangrelor in fourth quarter of 2012. The Company accepted the recommendation of a […]
Global Development and Commercialization Agreement to Begin with Co-Promotion of BRILINTA (ticagrelor) in United States WILMINGTON, Del. & PARSIPPANY, N.J., Apr 25, 2012 (BUSINESS WIRE) –AstraZeneca (NYSE: AZN) and The Medicines Company (NASDAQ: MDCO) announced today a global collaboration for acute ischemic heart disease compounds. Read More
MALVERN, PA (February 21, 2012) – Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, today secured $15 million in venture debt financing from Silicon Valley Bank and Oxford Finance. The New Drug Application (NDA) for Ceptaris’ drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the […]
PRINCETON, N.J., Feb. 15, 2012 /PRNewswire via COMTEX/ — IntegriChain Inc., a commercial provider of data and analytic insights to the pharmaceutical industry, announced today the introduction of a new methodology for its DNA: Inventory – Retail solution that adds the ability to report on independent and chain pharmacies’ inventory levels, by product NDC code, […]
PARSIPPANY, N.J., Feb. 14, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of a three-year agreement with a current Top 5 global pharmaceutical client and renewal of a one-year engagement with a specialty pharmaceutical client. Approximately $48 million in revenue is expected to be generated in 2012 between both contracts. Read more […]
By: Lt. Governor Kim Guadagno Since taking office in January 2010, Governor Chris Christie has chosen a new direction for New Jersey – lowering taxes, reducing bureaucracy that stifles economic development, and restructuring government so that the Garden State is a place where business growth is fostered and encouraged. Read more of this entry
A new study by Select Greater Philadelphia finds that the region is a top U.S. center for research and development (R&D) activity, a key to economic growth. Select found that Greater Philadelphia is among the nation’s top five R&D hubs… from Momentum!
The state known as the world’s “medicine chest” has seen a lot of changes in recent years, but a new report suggests New Jersey is still one of the top places for pharmaceutical and biotech firms to do business. Read more of this entry
Daily updates about the region's most tech savvy companies
